TGFB1 and cancer: The association of a more advanced stage and poorer overall survival with a low W-E signature in most Cluster 2 cancer types (Fig. 3b) is probably attributed to the enrichment of EMT and TGF-β signaling in patients with a low W-E signature (Fig. 4 and Supplementary Fig. 11a, b) because these pathways have been associated with poor prognosis in several cancer types35–37.